Merck & Co., Inc. (MRK)
NYSE: MRK · Real-Time Price · USD
117.68
+1.77 (1.53%)
Mar 13, 2026, 9:39 AM EDT - Market open
Merck & Co. Revenue
In the year 2025, Merck & Co. had annual revenue of $65.01B with 1.31% growth. Merck & Co. had revenue of $16.40B in the quarter ending December 31, 2025, with 4.97% growth.
Revenue (ttm)
$65.01B
Revenue Growth
+1.31%
P/S Ratio
4.41
Revenue / Employee
$866,813
Employees
75,000
Market Cap
290.95B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 65.01B | 843.00M | 1.31% |
| Dec 31, 2024 | 64.17B | 4.05B | 6.74% |
| Dec 31, 2023 | 60.12B | 832.00M | 1.40% |
| Dec 31, 2022 | 59.28B | 10.58B | 21.72% |
| Dec 31, 2021 | 48.70B | 7.19B | 17.31% |
| Dec 31, 2020 | 41.52B | 2.40B | 6.13% |
| Dec 31, 2019 | 39.12B | -3.17B | -7.50% |
| Dec 31, 2018 | 42.29B | 2.17B | 5.41% |
| Dec 31, 2017 | 40.12B | 315.00M | 0.79% |
| Dec 31, 2016 | 39.81B | 309.00M | 0.78% |
| Dec 31, 2015 | 39.50B | -2.74B | -6.48% |
| Dec 31, 2014 | 42.24B | -1.80B | -4.08% |
| Dec 31, 2013 | 44.03B | -3.23B | -6.84% |
| Dec 31, 2012 | 47.27B | -780.00M | -1.62% |
| Dec 31, 2011 | 48.05B | 2.06B | 4.48% |
| Dec 31, 2010 | 45.99B | 18.56B | 67.66% |
| Dec 31, 2009 | 27.43B | 3.58B | 15.00% |
| Dec 31, 2008 | 23.85B | -347.70M | -1.44% |
| Dec 31, 2007 | 24.20B | 13.60B | 128.41% |
| Dec 31, 2006 | 10.59B | 1.09B | 11.42% |
| Dec 31, 2005 | 9.51B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Johnson & Johnson | 94.19B |
| Pfizer | 62.58B |
| AbbVie | 61.16B |
| AstraZeneca | 58.74B |
| Novartis AG | 56.67B |
| Sanofi | 54.85B |
| Novo Nordisk | 48.59B |
| Bristol-Myers Squibb Company | 48.19B |
MRK News
- 2 days ago - Harbor Health Care ETF Q4 2025 Portfolio Review - Seeking Alpha
- 9 days ago - NeOnc Technologies Reports Phase 1 Dose-Escalation Results for Dosing and Toxicity and Determination of Recommended Phase 2 Dose for Oral NEO212; Management to Host KOL Conference Call Today at 9 a.m. ET - GlobeNewsWire
- 9 days ago - Merck & Co., Inc. (MRK) Presents at TD Cowen 46th Annual Health Care Conference Transcript - Seeking Alpha
- 9 days ago - AI-Powered Tempus Inks New Multi-Year Merck Deal - Benzinga
- 12 days ago - KEYTRUDA® (pembrolizumab) Plus WELIREG® (belzutifan) Given as Adjuvant Therapy Reduced the Risk of Disease Recurrence or Death by 28% Compared to KEYTRUDA Monotherapy in Certain Patients With Earlier-Stage Renal Cell Carcinoma (RCC) - Business Wire
- 12 days ago - WELIREG® (belzutifan) Plus LENVIMA® (lenvatinib) Reduced the Risk of Disease Progression or Death by 30% Compared to Cabozantinib in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC) - Business Wire
- 13 days ago - Merck to lay off around 150 employees at US site amid slump in Gardasil sales - Reuters
- 13 days ago - KEYTRUDA® (pembrolizumab) Plus Paclitaxel With or Without Bevacizumab Significantly Improved Key Secondary Endpoint of Overall Survival (OS) Versus Paclitaxel With or Without Bevacizumab in Patients With Platinum-Resistant Recurrent Ovarian Cancer - Business Wire